Vismodegib (GDC-0449)

For research use only. Not for use in humans.

目录号：S1082 中文名称：维莫德吉

Vismodegib (GDC-0449) Chemical Structure

CAS No. 879085-55-9

Vismodegib (GDC-0449)是一种新型有效的，特异性hedgehog抑制剂，无细胞试验中IC50为3 nM，也会抑制P-gp，IC50为3.0μM。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1179.52	现货
5mg	RMB 730.63	现货
10mg	RMB 1398.12	现货
50mg	RMB 3046.91	现货
100mg	RMB 5135.45	现货
200mg	RMB 8763.3	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Vismodegib (GDC-0449)发表文献140篇：

Nat Med, 2018, 24(11):1752-1761

PubMed: 30349086 ( click the link to review the publication )

Nat Med, 2018, 24(3):271-281

PubMed: 29400712 ( click the link to review the publication )

Nat Med, 2017, 23(10):1191-1202

PubMed: 28892064 ( click the link to review the publication )

Nature, 2016, 535(7613):517-22

PubMed: 27437577 ( click the link to review the publication )

Nature, 2014, 3;511(7507):90-3.

PubMed: 24870236 ( click the link to review the publication )

Nat Med, 2014, 20(9):1035-42

PubMed: 25150496 ( click the link to review the publication )

Nat Med, 2014, 20(7):732-40

PubMed: 24973920 ( click the link to review the publication )

Cancer Cell, 2014, 26(1):33-47

PubMed: 24954133 ( click the link to review the publication )

Gastroenterology, 2012, 143(5):1319-29.e1-11

PubMed: 22885334 ( click the link to review the publication )

Genes (Basel), 2021, 12(1)E120

PubMed: 33477943 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5079

PubMed: 33033234 ( click the link to review the publication )

Nucleic Acids Res, 2020, 48(18):10342-10352

PubMed: 32894284 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Theranostics, 2020, 10(4):1719-1732

PubMed: 32042332 ( click the link to review the publication )

Cancer Res, 2020, 5 pii: canres

PubMed: 32371475 ( click the link to review the publication )

Cells, 2020, 10(1)E53

PubMed: 33396427 ( click the link to review the publication )

Aging (Albany NY), 2020, 10.18632/aging.103230

PubMed: 32544883 ( click the link to review the publication )

Carcinogenesis, 2020, 41(7):993-1004

PubMed: 31740922 ( click the link to review the publication )

Front Oncol, 2020, 10:563838

PubMed: 33312948 ( click the link to review the publication )

Front Cell Neurosci, 2020, 14:575690

PubMed: 33343302 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00504-4

PubMed: 32855528 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00514-2

PubMed: 32958873 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )
Dev Biol, 2020, 457(1):128-139

PubMed: 31550483 ( click the link to review the publication )

PLoS One, 2020, 29;15(4):e0231762

PubMed: 32348319 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Oncotarget, 2020, 11(33):3174-3187

PubMed: 32913560 ( click the link to review the publication )

JCI Insight, 2020,

PubMed: 32814713 ( click the link to review the publication )

Sci Rep, 2020, 10(1):13400

PubMed: 32770014 ( click the link to review the publication )

J Clin Invest, 2019, 129(12):5151-5162

PubMed: 31638600 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(26):12986-12995

PubMed: 31182587 ( click the link to review the publication )

J Invest Dermatol, 2019, 139(7):1439-1448

PubMed: 30707899 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31601026 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):952

PubMed: 31844040 ( click the link to review the publication )

Endocr Relat Cancer, 2019, 10.1530/ERC-18-0538

PubMed: 30645190 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):364

PubMed: 31791391 ( click the link to review the publication )

ACS Chem Biol, 2019, 14(3):348-355

PubMed: 30763062 ( click the link to review the publication )

Lab Invest, 2019, 10.1038/s41374-019-0346-2

PubMed: 31758086 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)

PubMed: 31480400 ( click the link to review the publication )

Sci Rep, 2019, 9(1):19623

PubMed: 31873117 ( click the link to review the publication )

Sci Rep, 2019, 9(1):3353

PubMed: 30833624 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

J Biol Chem, 2019, 294(9):3284-3293

PubMed: 30573683 ( click the link to review the publication )

J Biol Chem, 2019, 294(25):9787-9798

PubMed: 30992365 ( click the link to review the publication )

Front Pharmacol, 2019, 10:89

PubMed: 30846937 ( click the link to review the publication )

Front Genet, 2019,

PubMed: 31867038 ( click the link to review the publication )
Toxicol Lett, 2019, 313:30-41

PubMed: 31181250 ( click the link to review the publication )

Oncol Rep, 2019, 41(1):437-446

PubMed: 30365081 ( click the link to review the publication )

PLoS One, 2019, 14(12):e0226570

PubMed: 31860685 ( click the link to review the publication )

PLoS One, 2019, 14(9):e0214901

PubMed: 31539380 ( click the link to review the publication )

Int J Oral Sci, 2019, 11(1):3

PubMed: 30783111 ( click the link to review the publication )

Phytomedicine, 2019, 67:153163

PubMed: 31901891 ( click the link to review the publication )

Nat Cell Biol, 2018, 20(8):909-916

PubMed: 30038251 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2897

PubMed: 30042390 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Sci Signal, 2018, 11(547)eaau5147

PubMed: 30206138 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(4):357-369

PubMed: 29396292 ( click the link to review the publication )

Oncoimmunology, 2018, 8(3):1548241

PubMed: 30723576 ( click the link to review the publication )

Eur J Med Chem, 2018, 156:554-562

PubMed: 30025349 ( click the link to review the publication )

Toxicol Sci, 2018, 166(2):394-408

PubMed: 30496568 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

Cancer Res, 2017, 77(12):3217-3230

PubMed: 28515149 ( click the link to review the publication )

J Control Release, 2017, 261:105-112

PubMed: 28662901 ( click the link to review the publication )

Oncogene, 2017, 36(32):4641-4652

PubMed: 28368412 ( click the link to review the publication )

Oncogene, 2017, 36(45):6306-6314

PubMed: 28714964 ( click the link to review the publication )

Br J Cancer, 2017, 117(9):1314-1325

PubMed: 28881358 ( click the link to review the publication )

Cancer Discov, 2017,

PubMed: 28923910 ( click the link to review the publication )

Sci Rep, 2017, 7(1):3815

PubMed: 28630423 ( click the link to review the publication )

Sci Rep, 2017, 7(1):13379

PubMed: 29042665 ( click the link to review the publication )

Am J Pathol, 2017, 187(5):1068-1092

PubMed: 28315313 ( click the link to review the publication )
Cancer Chemother Pharmacol, 2017, 79(2):411-420

PubMed: 28110457 ( click the link to review the publication )

Anticancer Drugs, 2017, 28(10):1106-1117

PubMed: 28799948 ( click the link to review the publication )

J Craniofac Surg, 2017, 28(6):1607-1614

PubMed: 28863112 ( click the link to review the publication )

Oncotarget, 2017, 8(47):82123-82143

PubMed: 29137250 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103744-103757

PubMed: 29262597 ( click the link to review the publication )

Cell Cycle, 2017, 16(14):1357-1365

PubMed: 28562206 ( click the link to review the publication )

Cell Mol Immunol, 2017, 14(2):214-222

PubMed: 26189371 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29371980 ( click the link to review the publication )

Oncotarget, 2017, 8(30):48660-48670

PubMed: 27750213 ( click the link to review the publication )

Hepatology, 2016, 63(4):1155-69

PubMed: 26473743 ( click the link to review the publication )

NATURE COMMUNICATIONS, 2016, 10.1038/ncomms10993

PubMed: 27001906 ( click the link to review the publication )

Nat Commun, 2016, 7:11151

PubMed: 27039827 ( click the link to review the publication )

Cancer Res, 2016, 76(24):7168-7180

PubMed: 27913436 ( click the link to review the publication )

Cancer Res, 2016, 76(18):5538-49

PubMed: 27488530 ( click the link to review the publication )

Arthritis Rheumatol, 2016, 68(10):2432-43

PubMed: 27159076 ( click the link to review the publication )

Cell Death Dis, 2016, 7(9):e2376

PubMed: 27899820 ( click the link to review the publication )

Stem Cells, 2016, 34(1):55-66

PubMed: 26418365 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Oxid Med Cell Longev, 2016, 2016:9826726

PubMed: 27143997 ( click the link to review the publication )

Sci Rep, 2016, 6:22540

PubMed: 26931153 ( click the link to review the publication )

Clin Lung Cancer, 2016, 17(4):301-8

PubMed: 26762562 ( click the link to review the publication )

Mol Med Rep, 2016, 13(2):1434-40

PubMed: 26676867 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26936993 ( click the link to review the publication )

Sci Rep, 2016, 6:20189

PubMed: 26846842 ( click the link to review the publication )
Clin Cancer Res, 2015, 21(20):4686-97

PubMed: 26124204 ( click the link to review the publication )

PLoS Genet, 2015, 11(6):e1005214

PubMed: 26091072 ( click the link to review the publication )

Development, 2015, 142(19):3374-82

PubMed: 26293299 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(4):1337-52

PubMed: 26101701 ( click the link to review the publication )

Mol Carcinog, 2015, 10.1002/mc.22300

PubMed: 25728352 ( click the link to review the publication )

Breast Cancer Res Treat, 2015,

PubMed: 25904215 ( click the link to review the publication )

Cell Cycle, 2015, 747:71-87

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(1):31-45

PubMed: 25496115 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0116390

PubMed: 25775002 ( click the link to review the publication )

PLoS One, 2015, 10(10):e0139830

PubMed: 26439749 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 457(3):318-23

PubMed: ( click the link to review the publication )

Oncol Lett, 2015, 9(6):2675-2679

PubMed: 26137127 ( click the link to review the publication )

Oncotarget, 2015, 6(30):28895-910

PubMed: 26336820 ( click the link to review the publication )

Sci Rep, 2015, 5:7915

PubMed: 25604826 ( click the link to review the publication )

Cell Rep, 2014, 8(5):1405-18

PubMed: 25176648 ( click the link to review the publication )

J Exp Clin Cancer Res, 2014, 33:34

PubMed: 24758269 ( click the link to review the publication )

Mol Pharmacol, 2014, 83(5):1020-9

PubMed: 23448715 ( click the link to review the publication )

Ann Surg Oncol, 2014, 21(8):2684-98

PubMed: 24682719 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2014, 21(8):2684-98

PubMed: 24450438 ( click the link to review the publication )

Pharmacol Res Perspect, 2014, 2(3):e00043

PubMed: 25505589 ( click the link to review the publication )

Universite Pierre et Marie Curie , 2014, LEPRIEUR EP

PubMed: ( click the link to review the publication )

Pharmacology Research Perspectives, 2014, 10.1002/prp2.43

PubMed: ( click the link to review the publication )

Gut, 2013, 62(2):299-309

PubMed: 22362915 ( click the link to review the publication )

Hepatology, 2013, 58(4):1362-74

PubMed: 23703673 ( click the link to review the publication )
Clin Cancer Res, 2013, 19(6):1422-32

PubMed: 23319824 ( click the link to review the publication )

Thyroid, 2013, 23(9):1119-26

PubMed: 23410206 ( click the link to review the publication )

Cancer Lett, 2013, 329(1):74-83

PubMed: 23111106 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(1):37-48

PubMed: 24233399 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2013, 147(1):508-16

PubMed: 24094913 ( click the link to review the publication )

Drug Metab Dispos, 2013, 41(10):1805-12

PubMed: 23868912 ( click the link to review the publication )

PLoS One, 2013, 8(6):e65032

PubMed: 23762282 ( click the link to review the publication )

PLoS One, 2013, 8(9):e74141

PubMed: 24066108 ( click the link to review the publication )

PLoS One, 2013, 8(3):e57346

PubMed: 23483902 ( click the link to review the publication )

Hematology, 2013, 88(4):265-72

PubMed: 23475625 ( click the link to review the publication )

Liver Int, 2013, 33(1):149-61

PubMed: 23121638 ( click the link to review the publication )

Gut, 2012, 61(9):1323-9

PubMed: 22427237 ( click the link to review the publication )

Cancer Res, 2012, 72(22):5912-20

PubMed: 22986746 ( click the link to review the publication )

ACS Chem Biol, 2012, 7(6):1040-8

PubMed: 22554036 ( click the link to review the publication )

Stem Cells Dev, 2012, 21(16):2939-48

PubMed: 22642671 ( click the link to review the publication )

Chem Biol, 2012, 19(8):972-82

PubMed: 22921064 ( click the link to review the publication )

Hepatology, 2011, 54(5):1580-90

PubMed: 21793033 ( click the link to review the publication )

Mol Cancer, 2011, 10:66

PubMed: 21619683 ( click the link to review the publication )

PLoS One, 2011, 6(9):e23943

PubMed: 21912653 ( click the link to review the publication )

J Neurooncol, 2011, 105(3):475-83

PubMed: 21633906 ( click the link to review the publication )

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

产品描述

Vismodegib (GDC-0449)是一种新型有效的，特异性hedgehog抑制剂，无细胞试验中IC50为3 nM，也会抑制P-gp，IC50为3.0μM。

靶点

Hedgehog ^[1]
(Cell-free assay)

3 nM

体外研究

GDC-0449有效抑制hedgehog通路，是一种新型及特定合成的小分子抑制剂，IC50为3nM。^[1] GDC-0449作用于Hedgehog信号通路，阻断Hedgehog配位体，即细胞表面受体PTCH 及SMO的活性，从而阻断Hedgehog信号通路。在组织生长和修复方面，Hedgehog信号通路意义重大。Hedgehog通路信号的异常激活，及不受控制的细胞增殖，可能与Hedgehog配位体，即细胞表面受体PTCH 及SMO的突变有关。在体外，GDC-0449在不抑制胰脏细胞增殖的前提下阻止原代胰脏移植物的生长，这项结果最近已经应用到临床。GDC-0449也抑制ABCG2, P-糖蛋白, 及和MDR有关联的重要MRP1 ABC载体。GDC-0449也阻断其他多种ABC载体。ABC载体属于一个膜蛋白家族，它的过量表达和耐药性有关，这也是治疗癌症的一个重大障碍。GDC-0449强抑制两种ABC载体，ABCG2/BCRP和ABCB1/P-糖蛋白，也温和抑制ABCC1/MRP1。在ABCG2过量表达的HEK293细胞中, GDC-0449可以提高荧光ABCG2底物BODIPY-哌唑嗪的保持力，也可用米托蒽醌再次处理这些细胞，产生抗肿瘤的ABCG2底物。实验使Madin-Darby犬的肾脏细胞中过量表达P糖蛋白或者MRP1，GDC-0449 提高了钙黄绿素-AM的保持力，然后载用秋水仙素处理这些细胞。另外，用米托蒽醌,托泊替康,SN-38处理的过量表达ABCG2的人类非小细胞肺癌细胞NCI-H460/par和NCI-H460/MX20，用GDC-0449再次处理。GDC-0449 作用于ABCG2 和 Pgp 的IC50值分别为1.4μM和 3.0 μM。^[2]GDC-0449 改变细胞内Ca²⁺ 平衡，且作用于抗cisplatin的肺癌细胞，抑制细胞生长。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
IGROV-1	Mn71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlLMTWM2OD1yLkC3NlQ5KM7:TR?=	NUThPG93RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
HCE-T	NETrN3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYLJR\|UxRTFwM{KyOFch\|ryP	M1XqNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
D-542MG	NVXRUW57T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYfJR\|UxRTFwOE[3N\|ch\|ryP	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
23132-87	MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVnmZ2NCUUN3ME20MlQxOTR5IN88US=>	NF;iXXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
HDLM-2	NYfPNnRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXLJR\|UxRThwMES3OlYh\|ryP	MnvaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
ACN	MkLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUjkPHN2UUN3ME24MlUxOTB7IN88US=>	M{K4fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
HuO-3N1	NUj1Z4VuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1[2dmlEPTB;OT62NFExQCEQvF2=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
BHT-101	M{LCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFfLTlBKSzVyPUGxMlM5KM7:TR?=	M4i1NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
KYSE-150	NUjNN\|l{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIjGOI1KSzVyPUGxMlU5PDFizszN	M1fHUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
MC-IXC	MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXXyWpdNUUN3ME2xNk4zOjl{IN88US=>	M{jjZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
D-423MG	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MoOyTWM2OD1zMj63OlU4KM7:TR?=	M324N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
NY	MmnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MX;JR\|UxRTF2Lki5NFMh\|ryP	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
HOS	M3HV[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYjMfZdDUUN3ME2xOU43PzF7IN88US=>	MmG0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
NB7	NXLETmpGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXjJR\|UxRTF3Lki5NUDPxE1?	NHPqbJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
DMS-273	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmrHTWM2OD1zNj62O\|E{KM7:TR?=	M4DRTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
MDA-MB-361	M4m5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnvqTWM2OD1zNz6yO\|EyKM7:TR?=	M1H2dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
DU-145	NG\GWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NH3wPJNKSzVyPUG4MlMzKM7:TR?=	NYDqbpZ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
NCI-H82	NVO1dlZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NX74SW9CUUN3ME2xPU45Ozh4IN88US=>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
NCI-SNU-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXjJR\|UxRTJyLkCxPVYh\|ryP	M2fId\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
GCT	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUHJR\|UxRTJyLki4NlQh\|ryP	M3OyWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
C2BBe1	NWPGSpA{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mm\WTWM2OD1{MT6xNFU5KM7:TR?=	NIjITXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
LB2241-RCC	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{\qbWlEPTB;MkGuPFQ1OSEQvF2=	NIG5PZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
COLO-829	NWjBbJBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYfnfJo6UUN3ME2yNk4yQDdzIN88US=>	MorFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
EW-11	M1X5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4nWTGlEPTB;MkKuPFAzOiEQvF2=	NIHMZZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
NCI-H526	NGK5NndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3v6VWlEPTB;MkOuOFcyPyEQvF2=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
SF295	NY[zOWtzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWTJR\|UxRTJ2LkCyOVIh\|ryP	MlXhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
D-566MG	NH\YZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mn;OTWM2OD1{NT6yPVQ{KM7:TR?=	MljmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
8505C	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NH7OVJhKSzVyPUK1MlY{OzFizszN	MmLwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
HT-29	M3HxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1P1VGlEPTB;Mk[uNFQ{OSEQvF2=	M{LhN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
NBsusSR	NV34VFhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4XyRWlEPTB;Mk[uPFAxPiEQvF2=	M4rLWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
BV-173	NXfBcYRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEL0NHpKSzVyPUK4MlMyQDJizszN	M{H4W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
CTB-1	NUnHbW9GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mnm2TWM2OD1\|MD6xNFMyKM7:TR?=	M1vH[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
JAR	NIDneodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1HLXmlEPTB;M{KuOVM4OSEQvF2=	NH7PTXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
CAMA-1	NXnucXZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkjaTWM2OD1\|Mz60OlE2KM7:TR?=	NUnCUGwxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
CAL-51	NG[5SJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1[zdmlEPTB;M{SuO\|E4PiEQvF2=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
A172	NHHHblFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXnyZpRpUUN3ME2zO{41QTJzIN88US=>	NXrJNGJqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
QIMR-WIL	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MX\JR\|UxRTN6LkC3NFgh\|ryP	NFOwXFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
AsPC-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXLRO2VuUUN3ME2zPE41PjVzIN88US=>	MlLsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
MKN7	MmfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NEDOTlVKSzVyPUO5MlAxPzlizszN	Mm\oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
ONS-76	NYfVdFhrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYn5TnB[UUN3ME20N{4{ODV5IN88US=>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
RS4-11	M4H6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1eyW2lEPTB;NESuNFc2OiEQvF2=	NV34TopQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
NOS-1	NInte4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVrJR\|UxRTR2Lk[wN\|Eh\|ryP	NEjiPYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
A101D	NIfFem1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MoDzTWM2OD12ND64NFI{KM7:TR?=	NGfxOFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
HCC1806	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYHJR\|UxRTR4LkGxOFgh\|ryP	M1vPflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
CAL-27	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmC4TWM2OD12Nz63NlQ3KM7:TR?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
BT-549	Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoryTWM2OD12OD61N\|E2KM7:TR?=	M{fzXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
LCLC-97TM1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFTCOFBKSzVyPUS5MlI1OTNizszN	M2fJUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
A4-Fuk	NULi[4luT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Ml\oTWM2OD12OT64OFkh\|ryP	NILXNGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
OVCAR-4	NHHxVFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFPVVG9KSzVyPUWwMlA3ODFizszN	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
HD-MY-Z	MlzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVXz[mJSUUN3ME21NE44PzZ2IN88US=>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
NCI-H292	NYTCWmRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWnGXpVLUUN3ME21NE45PzV6IN88US=>	NH[xWWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
Sk-ChA-1	NITjUZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLpUHZmOC5{NfMAl\|UxKM7:TR?=	MknJO\|IhcA>?	Mn35TWM2OD15ND61OOKyOi53ON88US=>	MnW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NEK0PFIoRjJ3N{SyOFgzRC:jPh?=
Mz-ChA-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVywMlI26oDVNUCg{txO	M1faZ\|czKGh?	Mof6TWM2OD13ND65O:KyOy52Nd88US=>	NFPsVnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0NlQ5Oid-MkW3OFI1QDJ:L3G+
Smo-WT	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NISxcmFKSzVywrDv[kAyPMLibl2=	MoKxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUGxNFQoRjJ2MkmxNVA1RC:jPh?=
Smo-D473H	NX;SR5pIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXS0UIU3UUN3MNMgc4YhPy5zwrFOwG0>	NInTeWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5NVExPCd-MkSyPVEyODR:L3G+
K562	MWLGeY5kfGmxbjDBd5NigQ>?	MnPrNVAh\|ryP	NIDmRoo4OiCq	MWTy[YR2[2W\|IITo[UBmgHC{ZYPzbY9vKG:oIFfsbVHDqA>?	NXXufWJmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVk5OjRpPkKzN\|E6QDJ2PD;hQi=>
T315I BCR-ABL BaF3	NES2bnJHfW6ldHnvckBCe3OjeR?=	NXrMTmFDOTBizszN	NILZb3E4OiCq	NUG0OGJoemWmdXPld{B1cGViZYjwdoV{e2mxbjDv[kBIdGlzwrC=	Mn\mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUm4NlQoRjJ\|M{G5PFI1RC:jPh?=
TF-1 BCR-ABL	NXfFZ\|VRTnWwY4Tpc44hSXO\|YYm=	Mkf2NVAh\|ryP	NHXub204OiCq	M33GZpJm\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gS4xqOcLi	NVLUTYxZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVk5OjRpPkKzN\|E6QDJ2PD;hQi=>
Shh-Light 2	M3TvSWZ2dmO2aX;uJIF{e2G7		MXyyJIRigXN?	MVvBcpRi\2:waYP0JIFkfGm4aYT5JIF1KFOvbzDpckBud3W\|ZTDTbIguVGmpaISgNkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGPobE1qdmS3Y3XkJGdtcTFvcnXwc5J1\XJiYXP0bZZqfHliYX\0[ZIhOiCmYYnzJIJ6KGS3YXytcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIH3leIhw\CxiSVO1NEA:KDBwMECxOUDPxE1w	NUXsc2JERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlM2OjJpPkKzNFY{PTJ{PD;hQi=>
NIH/3T3	MVzGeY5kfGmxbjDhd5NigQ>?			NIKzbHhKdmirYnn0bY9vKG:oIHjl[IdmcG:pIIPp[45idGmwZzCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGK7IFfsbU1lfWGuLXz1Z4ln\XKjc3WgdoVxd3K2ZYKgZZN{[XluIFnDOVAhRSByLkCwNlMh\|ryPLh?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF6MECxNkc,OjdzOECwNVI9N2F-
NIH/3T3 Light2	MlP3SpVv[3Srb36gZZN{[Xl?			NFLQUoNKdmirYnn0bY9vKG:oIHjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIF7JTE8{XDNiTHnnbJQzKGOnbHzzJIJ6KEeuaT3seYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjByMkOg{txONg>?	MmPEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4OEiyO\|goRjJ6Nki4Nlc5RC:jPh?=
Light2	MVvGeY5kfGmxbjDhd5NigQ>?		MlvjOFghcHK\|	MkHOTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCOaXfoeFIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IFfsbU1tfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVAhRSByLkCwNlQ3KM7:TT6=	NYPWeZNGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3N\|k4OTRpPkK5O\|M6PzF2PD;hQi=>
HEPM	MnT5SpVv[3Srb36gZZN{[Xl?			M3nWemlvcGmkaYTpc44hd2ZiU1jIJIlvKGi3bXHuJGhGWE1iY3XscJMh[nliR3zpMYx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSV7IJF0hOC5yMEK4JO69VS5?	Mor2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5MU[yPVYoRjF7N{G2Nlk3RC:jPh?=
Shh Light2	NVLSbpVbTnWwY4Tpc44h[XO\|YYm=			NEHZU2lKdmirYnn0bY9vKG:oIGPITEBqdiCvb4Xz[UBUcGhiTHnnbJQzKGOnbHzzJIJ6KEeOST3y[ZNxd26\|aY\lJIZqemWobImgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwJF0hOC5yMEOg{txONg>?	NUL4cnFMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzNFkxQDBpPkG5N\|A6ODhyPD;hQi=>
HEPM	MoLnSpVv[3Srb36gZZN{[Xl?			NUf4XI1jUW6qaXLpeIlwdiCxZjDI[YRo\WixZzDzbYdv[WyrbnegbY4hcHWvYX6gTGVRVSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gdoVk\XC2b4KtcYVlcWG2ZXSgS4xqOSCvUl7BJIV5eHKnc4Ppc44h[nlicnXwc5J1\XJiZ3Xu[UBie3OjeTygTW5JKD1iMD6wNFMh\|ryPLh?=	MnzxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6N{W3OFEoRjJyOEe1O\|QyRC:jPh?=
C3H10T1/2	NEWzO5NHfW6ldHnvckBie3OjeR?=		M3\yTVIxKGi{cx?=	MXnJcohq[mm2aX;uJI9nKFOvbzDpckBud3W\|ZTDDN2gyOFRzL{KgZ4VtdHNidYPpcochcHWvYX6gdoVkd22kaX7hcpQhW0iKIHHzd4V{e2WmIHHzJIVn\mWldDDvckBUVU9xU1jIJJRz[W6\|aXXueEB1emGwc3PybZB1cW:wYXygZYN1cX[jdHnvckBi\nSncjCyNEBpenNiYomgS4xqNWy3Y3nm[ZJie2VicnXwc5J1\XJiYYPzZZktKEmFNUCgQUAxNjByNTFOwG0v	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMESzOkc,OjR7MEC0N\|Y9N2F-
NIH/3T3	NGKxcGJHfW6ldHnvckBie3OjeR?=		MYGyOEBpenN?	MkHYTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCQSVivN3Q{KGOnbHzzJI1m[XO3cnXkJIFnfGW{IEK0JIhzeyCkeTDHcIku\HWjbDDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjByNTFOwG0v	NWPsb5lrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4NVA2QTFpPkK3PFExPTlzPD;hQi=>
NIH3T3	M3PjUmZ2dmO2aX;uJIF{e2G7		NUP6c4RGPDhiaILz	MoLCTY5pcWKrdHnvckBw\iC\|bX:tcYVlcWG2ZXSgbIVl\2Wqb3egd4lodmGuaX7nJJBifGi5YYmgbY4hdW:3c3WgUmlJO1R\|IHPlcIx{KGW6cILld5NqdmdiR2LFMWx2[yC{ZYDvdpRmeiCpZX7lJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gV2FINWmwZIXj[YQhT1KHLVz1Z{Bz\XCxcoTldkBi[3Srdnn0fUBi\nSncjC0PEBpenNiYomgcJVucW6nc3PlcoNmKGG\|c3H5MEBKSzVyIE2gNE4xODZizszNMi=>	Mnv5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2OUm0PFMoRjJ7NEm5OFg{RC:jPh?=
Shh-light2	MWnGeY5kfGmxbjDhd5NigQ>?			M2fhNWlvcGmkaYTpc44hd2ZiU33vMY1m\GmjdHXkJGhpKHOrZ37hcIlv\yCrbjDoeY1idiCVaHitcIlocHR{IHPlcIx{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvODB5IN88UU4>	NUnSXHdRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOlg2PTFpPkKyNlY5PTVzPD;hQi=>
HEK293	NVPo[ml2TnWwY4Tpc44h[XO\|YYm=		NVr1WVZFOiCqcoO=	M13YUGRqe3CuYXPlcYVvfCCxZjDCU2RKWFlvbHHi[Yxt\WRiY4njcI9x[W2rbnWg[pJwdSCqdX3hckBUdW9icnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjZoTldkAzKGi{czDifUBndHWxcnXzZ4Vv[2VibXnjdo9{[2:yeTygTWM2OCB;IECuNFA4KM7:TT6=	NETHSpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK2PFU2OSd-MkKyOlg2PTF:L3G+
NIH3T3	NUeyZmtGTnWwY4Tpc44h[XO\|YYm=			NXT5PXhsUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDy[YNmeHSxcjDzbYdv[WyrbnegdIF1cHejeTDpckBud3W\|ZTDOTWg{XDNiY3XscJMhfHKjboPm[YN1\WRid3n0bEBIdGlvcnXwc5J1\XJiZ3Xu[UBjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGlEPTBiPTCwMlAxPzF5IN88UU4>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl{M{e2OUc,OjR7MkO3OlU9N2F-
NIH/3T3	NXSxUVdtTnWwY4Tpc44h[XO\|YYm=		M{PLfVQ5KGi{cx?=	NUjWbY1UUW6qaXLpeIlwdiCxZjDI[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBUd26rYzDo[YRo\WixZz3pcoR2[2WmIFfsbUBtfWOrZnXyZZNmKGGldHn2bZR6KGGodHXyJFQ5KGi{czDifUBFfWGuLXz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvODB5MUeg{txONg>?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ2OUS5OEc,OzB{NEm0PVQ9N2F-
NIH3T3	MYPGeY5kfGmxbjDhd5NigQ>?		MXS0PEBpenN?	NWXNWpB3UW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyuaX7nJIlvKG2xdYPlJG5KUDOWMzDj[YxteyC\|dHHicJkhfHKjboPm[YN1\WRid3n0bEBIdGlvbIXjbYZmemG\|ZTDjc45{fHK3Y4SgbY5kfWKjdHXkJIZweiB2ODDodpMh[nliZIXhcEBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVAhRSByLkCwO\|Ih\|ryPLh?=	M1rtUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OEK3NVM3Lz5{NkiyO\|E{PjxxYU6=
NIH3T3	M3noUmZ2dmO2aX;uJIF{e2G7		NFr1[VM1QCCqcoO=	MoG5TY5pcWKrdHnvckBw\iCVb37pZ{1qdmS3Y3XkJIhm\GenaH;nJJNq\26jbHzpcochcW5ibX;1d4UhVkmKM2SzJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCJbHmtcJVkcW[ncnHz[UBz\XCxcoTldkBie3OjeTygTWM2OCB;IECuNFA4OiEQvF2u	M3vxc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OEKwOVU1Lz5{NkiyNFU2PDxxYU6=
NIH3T3	M{DVdWZ2dmO2aX;uJIF{e2G7		M2Pp[VQ5KGi{cx?=	MkfBTY5pcWKrdHnvckBw\iCVSFigd4lodmGuaX7nJJBifGi5YYmgbY4hdW:3c3WgUmlJO1R\|IHPlcIx{KG2nYYP1doVlKGGodHXyJFQ5KGi{czDifUBIdGlvbIXjbYZmemG\|ZTDy[ZBwenSncjDhd5NigSxiSVO1NEA:KDBwMEC3NkDPxE1w	NGDZcFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG3OlM6Pid-MkSxO\|Y{QTZ:L3G+
NIH/3T3	NVXZfWc6TnWwY4Tpc44h[XO\|YYm=		MXi0PEBpenN?	MUPJcohq[mm2aX;uJI9nKGinZHflbI9oKHOrZ37hcIlv\yCyYYToe4F6KGmwIH3veZNmKE6LSD:zWFMh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IFfsbU1tfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVAhRSByLkCwO\|Ih\|ryPLh?=	MlfJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OE[yNFMoRjJ2NEi2NlA{RC:jPh?=
NIH/3T3	NIL0SJdHfW6ldHnvckBie3OjeR?=			NV7GXmpYUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGK7IFfsbVEudHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR\|UxKD1iMD6wNFczKM7:TT6=	M2fCUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEC1O\|A1Lz5{NESwOVcxPDxxYU6=
NIH/3T3	MWTGeY5kfGmxbjDhd5NigQ>?			NWjN[o5VUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGOjcoL5bY5oKHO2YXLsfUB1emGwc3\lZ5Rm\CCJbHmtdoVxd3K2ZYKgZ49ve3S{dXP0JIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiYYPzZZktKEmFNUCgQUAxNjByN{Kg{txONg>?	NWDERmtQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2OFIyODFpPkK4OlQzOTBzPD;hQi=>
C3H10T1/2	MnyzSpVv[3Srb36gZZN{[Xl?		MUS2JIhzew>?	M{TZTGlvcGmkaYTpc44hd2ZiU1HHMYlv\HWlZXSg[Iln\mW{ZX70bYF1cW:wIH;mJI1wfXOnIH3ld4Vv[2i7bXHsJJBtfXKrcH;0[Y51KEN\|SEGwWFEwOiClZXzsd{B1dyCjbHvhcIlv\SCyaH;zdIhifGG\|ZTDwc5NqfGm4ZTDv[ZNmd2KuYYP0d{Bi\nSncjC2JIhzeyxiSVO1NEA:KDBwMEGxJO69VS5?	M1r4b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mk[4OVUyLz5{MkK2PFU2OTxxYU6=
HCC827	M2HMbGZ2dmO2aX;uJIF{e2G7			M3LFbmRqe3CuYXPlcYVvfCCxZjDbN2heNWO7Y3zvdIFucW6nIH\yc40hW02RIG[0NFROKG23dHHueEBqdiCpZX\peIlvcWJicnXzbZN1[W62IHj1cYFvKEiFQ{iyO{Bk\WyuczDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDLbUA:KDBwMEGyNkDPxE1w	MnzNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5OEexOVYoRjJ6N{i3NVU3RC:jPh?=
C3H10T1/2	MY\GeY5kfGmxbjDhd5NigQ>?			M1nv[2lvcGmkaYTpc44hd2ZiU1jIJIlvKG2xdYPlJGM{UDFyVEGvNkBk\WyuczDifUBIdGlvbIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBKSzVyIE2gNE4xOTNizszNMi=>	M3rUdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{G2Nlk3Lz5zOUexOlI6PjxxYU6=
S12	MX;GeY5kfGmxbjDhd5NigQ>?			M4TLV2lvcGmkaYTpc44hd2ZiSHXk[4Vpd2dic3nncoFtcW6pIHnuJI1wfXOnIGOxNkBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5icnXj[ZB1d3JvbXXkbYF1\WRiR3zpNUBuWk6DIHX4dJJme3Orb36gZpkhemWyb4L0[ZIh\2WwZTDhd5NigSxiSV7IJF0hOC5yMUOg{txONg>?	MoXoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6N{W3OFEoRjJyOEe1O\|QyRC:jPh?=
TM3	Mn\QSpVv[3Srb36gZZN{[Xl?		MnrXOFghcHK\|	MnXtTY5pcWKrdHnvckBw\iCKaDDzbYdv[WyrbnegdIF1cHejeTDpckBud3W\|ZTDUUVMh[2WubIOgZZN{\XO\|ZXSgZZMh\G:5boLl[5Vt[XSrb36gc4YhT2yrMTDn[Y5mKGW6cILld5Nqd25iYX\0[ZIhPDhiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OCB;IECuNFE{KM7:TT6=	M4n5fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUe2NlE2Lz5{Nkm3OlIyPTxxYU6=
NIH/3T3	NFvhTGdHfW6ldHnvckBie3OjeR?=			M3\UXGlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViTlnIM\|NVOyClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCVbX:gZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIFfsbUBuWk6DIHX4dJJme3Orb36gZpkhWlRvUFPSJI1mfGixZDygTWM2OCB;IECuNFE1PCEQvF2u	MonVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6MUC1PVEoRjJ5OEGwOVkyRC:jPh?=
S12	MkOxSpVv[3Srb36gZZN{[Xl?		NF\zZWI1QCCqcoO=	NWDsU2wxUW6qaXLpeIlwdiCxZjDoeY1idiCVSFigdIF1cHejeTDpckBud3W\|ZTDTNVIh[2WubIOgZZN{\XO\|ZXSgZZMhT0yLLX3l[IlifGWmIITyZY5{[3KrcITpc45idCCjY4Tpeol1gSCjZoTldkA1QCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR\|UxKD1iMD6wNVUh\|ryPLh?=	MorPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2M{i1NlcoRjJzNEO4OVI4RC:jPh?=
NIH/3T3	NVqyVG9JTnWwY4Tpc44h[XO\|YYm=			M3;jemlvcGmkaYTpc44hd2ZiU13PJIlvKG2xdYPlJG5KUC9\|VEOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCVQVetbY5lfWOnZDDo[YRo\WixZz3t[YRq[XSnZDDseY1qdmW\|Y3XuZ4Uhe2mpbnHsbY5oKGK7IFfSSU1tfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVAhRSByLkCxOkDPxE1w	NH;sW5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxPVUxOCd-Mk[xNVk2ODB:L3G+
U2OS	NVzVbJM5TnWwY4Tpc44h[XO\|YYm=		M3;lNVIhcHK\|	NHLvfY9FcXOybHHj[Y1mdnRib3[gX\|NJZWO7Y3zvdIFucW6nIH\yc40hf2muZDD0fZBmKFOvbzDlfJBz\XO\|ZXSgbY4hXTKRUzDj[YxteyCjZoTldkAzKGi{czDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDLbUA:KDBwMEG2NkDPxE1w	NXXXVHFqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlM2OjJpPkKzNFY{PTJ{PD;hQi=>
NIH3T3	MmHNSpVv[3Srb36gZZN{[Xl?		NUf1SFh7OzBiaILz	MXzJcohq[mm2aX;uJI9nKFOvbzDy[YNmeHSxcjCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBPUUh\|VEOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCVbX:gZYdwdmm\|dDDTRWcucW6mdXPl[EBIWkViYXP0bZZifGmxbjDh[pRmeiB\|MDDodpMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBKSzVyIE2gNE4xOjNizszNMi=>	M16zbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{K2PFA4Lz5{NEeyOlgxPzxxYU6=
medulloblastoma cell	NYnvOm5RSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Ml;iN\|YhcHK\|	NIPXOopCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JHB1[2htLz2gZY5lKHB3Mz2vMUBud3W\|ZTDt[YR2dGyxYnzhd5RwdWFiY3XscJMh[W[2ZYKgN\|YhcHK\|IHL5JGJz\HViaX7jc5Jxd3KjdHnvckBie3OjeTygTWM2OCB;IECuNFMxPCEQvF2u	NW[weGVnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2PFgzPzhpPkK4Olg5Ojd6PD;hQi=>
Shh Light2	NYXTOWRbTnWwY4Tpc44h[XO\|YYm=			NF3nTYJCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IIPtc491cGWwZXSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgV4hpKEyrZ3j0NkBk\WyuczDjc{1mgHC{ZYPzbY5oKEeuaT3k[ZBmdmSnboSgdoVxd3K2ZYKg[4Vv\SCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEiqIIPp[45idGmwZzDifUBlfWGuIHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvODN\|IN88UU4>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7MUS1PUc,OjR2OUG0OVk9N2F-
Light2	MWLGeY5kfGmxbjDhd5NigQ>?			M2PCWGlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViTHnnbJQzKGOnbHzzJIlvKFOqaDDjc45lcXSrb37l[EBu\WSrdX2gZpkhT2yrLXz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvODN7IN88UU4>	M2fZclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEezN\|A{Lz5{OEi3N\|MxOzxxYU6=
Shh Light2	Mni1SpVv[3Srb36gZZN{[Xl?			MnL2TY5pcWKrdHnvckBw\iCVbX:tcYVlcWG2ZXSgTIghe2mpbnHscIlv\yCyYYToe4F6KGmwIH3veZNmKFOqaDDMbYdpfDJiY3XscJMh[nliR3zpMYx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDBwMEO5NkDPxE1w	MoHHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5M{[wOlMoRjJ5N{O2NFY{RC:jPh?=
ASZ001	NIXGRo5HfW6ldHnvckBie3OjeR?=		NGLIblc1QCCqcoO=	MVLJcohq[mm2aX;uJI9nKEinZHflbI9oKHOrZ37hcIlv\yCrbjDtc5V{\SCDU2qwNFEh[2WubIOgZZN{\XO\|ZXSgZZMh\G:5boLl[5Vt[XSrb36gc4YhT2yrMTDtVm5CKGW6cILld5Nqd25iYX\0[ZIhPDhiaILzJIJ6KFKWLWDDVkBidmGueYPpd{whUUN3MDC9JFAvODRizszNMi=>	NFq3XJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFcyPid-MkS5NFA4OTZ:L3G+
NIH/3T3	MnTnSpVv[3Srb36gZZN{[Xl?		MX[0PEBpenN?	MYfBcpRi\2:waYP0JIFkfGm4aYT5JIF1KFOvbzDy[YNmeHSxcjDpckBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGijcnLvdolv\yCJUlWtUJVkKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhW0GJLXnu[JVk\WRiSHigd4lodmGuaX7nJJBifGi5YYmgdJJmcW6ldXLheIVlKHerdHigZ4VtdHNiZn;scI94\WRiYomgV2FIKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFQ5KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVAhRSByLkC0OkDPxE1w	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTh3N{K3OUc,Ojl6NUeyO\|U9N2F-
Light2	MluySpVv[3Srb36gZZN{[Xl?		NV;vVI9zOzBiaILz	NVnheotXUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W\|ZTDMbYdpfDJiY3XscJMhcW5iU3joJINwdmSrdHnvcoVlKG2nZHn1cUBi\nSncjCzNEBpenNiYomgS4xqNVKnbnnscIEhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR\|UxKD1iMD6wOUDPxE1w	M{DFXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEm5NlU4Lz5\|MEC5PVI2PzxxYU6=
C3H10T1/2	MYfGeY5kfGmxbjDhd5NigQ>?		MWC2JIRigXN?	NYTU[2d3UW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeT3t[YRq[XSnZDDkbYZn\XKnboTpZZRqd25ib3[gcY92e2ViQ{PINVBVOS9{IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJHNCTy2rbnT1Z4VlKEGOUDDhZ5Rqfmm2eTDh[pRmeiB4IHThfZMh[nliY3jlcYltfW2rbnXzZ4Vv[2VvYnHz[YQh[XO\|YYmsJGlEPTBiPTCwMlA2KM7:TT6=	NFX2eXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC5PVI2Pyd-M{CwPVkzPTd:L3G+
DaOY	NYTHcXpZTnWwY4Tpc44h[XO\|YYm=		NITlN5M1QCCqcoO=	MmrCTY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC\|aXfuZYxqdmdiaX6gbJVu[W5iRHHPXUBk\WyuczDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBIdGlzIH3SUmEh\XiycnXzd4lwdiCjZoTldkA1QCCqcoOgZpkhWlRvUFPSJIFv[Wy7c3nzMEBKSzVyIE2gNE4xQDZizszNMi=>	NHfITIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFcyPid-MkS5NFA4OTZ:L3G+
C3H10T1/2	MUfGeY5kfGmxbjDhd5NigQ>?		MV2xJIhz	M1L5fGlvcGmkaYTpc44hd2ZiSHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViQ{PINVBVOS9{IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBxfXKvb4LwbIFucW6nLXnu[JVk\WRiaX7jdoVie2ViaX6gZYxs[WyrbnWgdIhwe3CqYYThd4UhdGW4ZXygeZNqdmdiQ1TQMZN1[XJiYYOgd5Vje3S{YYTlJJBz\XS{ZXH0[YQh\m:{IEGgbJIh\m:ubH;3[YQh[nlicIXycY9zeGijbXnu[UBi\GSrdHnvckBu\WG\|dYLl[EBi\nSncjC1JIRigSxiSVO1NEA:KDBwMUSg{txONg>?	MomxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NEe5N\|koRjJ6OUS3PVM6RC:jPh?=
M210B4	MUXGeY5kfGmxbjDhd5NigQ>?		NEnpeGkzPCCqcoO=	MmXrTY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC\|aXfuZYxqdmdiaX6gcY92e2ViTUKxNGI1KGOnbHzzJIF{e2W\|c3XkJIF{KGSxd37y[Yd2dGG2aX;uJI9nKFC2Y3igcXJPSSCneIDy[ZN{cW:wIHHmeIVzKDJ2IHjyd{BjgSCUVD3QR3Ih[W6jbInzbZMtKEmFNUCgQUAxNjF2IN88UU4>	NYLTO4lmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA4OTZpPkK0PVAxPzF4PD;hQi=>
M210B4	MXnGeY5kfGmxbjDhd5NigQ>?		M{XxOFI1KGi{cx?=	M1TSXWlvcGmkaYTpc44hd2ZiSHXk[4Vpd2dic3nncoFtcW6pIHnuJI1wfXOnIF2yNVBDPCClZXzsd{Bie3Onc4Pl[EBieyCmb4fudoVofWyjdHnvckBw\iCJbHmxJI1TVkFiZYjwdoV{e2mxbjDh[pRmeiB{NDDodpMh[nliUmStVGNTKGGwYXz5d4l{NCCLQ{WwJF0hOC5{IN88UU4>	M2PrUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwO\|E3Lz5{NEmwNFcyPjxxYU6=
Shh Light2	M4jYN2Z2dmO2aX;uJIF{e2G7		MlXJNUBpeg>?	MUnJcohq[mm2aX;uJI9nKEinZHflbI9oKHOrZ37hcIlv\yCrbjDtc5V{\SCVaHigUIlocHR{IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBxfXKvb4LwbIFucW6nLXnu[JVk\WRiR3zpJI1m\GmjdHXkJJRz[W6\|Y4LpdJRqd26jbDDhZ5Rqfmm2eTDwdoV1emWjdHXkJIZweiBzIHjyJIZwdGyxd3XkJIJ6KHC3cn3vdpBp[W2rbnWgZYRlcXSrb36gcYVie3W{ZXSgZYZ1\XJiNEigbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvQThizszNMi=>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl2N{mzPUc,Ojh7NEe5N\|k9N2F-
NIH/3T3	MoS2SpVv[3Srb36gZZN{[Xl?			NEm2VnVKdmirYnn0bY9vKG:oIHjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIF7JTE8{XDNiY3XscJMhcGG{Yn;ybY5oKFOvbzDEOFc4UCCvdYThcpQh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGdtcSCvUl7BJIV5eHKnc4Ppc44h[nliUmStVGNTKG2ndHjv[EwhUUN3MDC9JFEvOTl4IN88UU4>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzhzMEW5NUc,Ojd6MUC1PVE9N2F-
S12	MV7GeY5kfGmxbjDhd5NigQ>?		NF;TPGs1QCCqcoO=	NWnKUpN2UW6qaXLpeIlwdiCxZjDoeY1idiCVSFigdIF1cHejeTDpckBud3W\|ZTDTNVIh[2WubIOgZZN{\XO\|ZXSgZZMhT0yLLX3l[IlifGWmIITyZY5{[3KrcITpc45idCCjY4Tpeol1gSCjZoTldkA1QCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7IHnuJJBz\XOnbnPlJI9nKDBwNTDt[{9uVCCqdX3hckBidHCqYT2xMYFkcWRiZ3z5Z49xem:2ZXnuMEBKSzVyIE2gNU44PSEQvF2u	M3TRSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEO4OVI4Lz5{MUSzPFUzPzxxYU6=
Calu6	M3PzUWZ2dmO2aX;uJIF{e2G7		M{i1d\|QhcHK\|	NYPjNlB4WGyjc33hJINwdmOnboTyZZRqd25iaX6gbJVu[W5iQ3HseVYh[2WubIOgfIVvd2e{YX\0[YQhcW5iboXk[UBud3W\|ZTDheEA4PSCvZz;r[{wheG9iYnnkJI1m[XO3cnXkJIFnfGW{IESgbJJ{KHCxc4Sg[olnfGhiZH;z[UwhS3BiPTCyN{DPxE1w	NFXXd\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUexOlI6Pid-MUm3NVYzQTZ:L3G+
Calu-6	MoCxSpVv[3Srb36gZZN{[Xl?			NHraWYpRdGG\|bXGgZ49v[2WwdILheIlwdiCrbjDDZYx2NTZiY3XscJMhgGWwb3fyZYZ1\WRiboXk[UBud3W\|ZTDQT{9RTCCvb3TlcEBifCB5NTDt[{9s\yxicH:gZollKG[xcjC1JIRigXNibXXhd5Vz\WRiNDDodpMheG:\|dDDsZZN1KGSxc3WgdoVt[XSrdnWgeI8hfW62cnXheIVlKGOxboTyc4wtKEOyIE2gNlMh\|ryPLh?=	M{L4bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEe1O\|QyLz5{MEi3OVc1OTxxYU6=
T47D	M4j6OGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MnH5O\|IhcHK\|	M4r1RmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHQ1P0RiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFQyNjN2IN88UU4>	Mkf6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzMEe0NlkoRjJ7MUC3OFI6RC:jPh?=
LS180	MUDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NFvyZ3M4OiCqcoO=	MVzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEyVMUiwJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSC\|dXzmc5Jpd2SjbXnu[U1DKGG\|c3H5MEBKSzVyIE2gOFUh\|ryPLh?=	NEW4TJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC5PVI2Pyd-M{CwPVkzPTd:L3G+
LS174T	MmfVRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MUe3NkBpenN?	NVvObmZJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDMV\|E4PFRiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9ibIXtbY5me2OnboSgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1PS56MTFOwG0v	MoDHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6MkC1OVQoRjJ4OEKwOVU1RC:jPh?=
BxPC3	NGGwbJhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MWi3NkBpenN?	M3vtU2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQojQR\|Mh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdnRiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0O{46PSEQvF2u	NWO5bY9yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4NlA2PTRpPkK2PFIxPTV2PD;hQi=>
medulloblastoma cell	NUjhOYRvSW62aYT1cY9zKGG\|c3H5			MljyRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2VibXXkeYxtd2KuYYP0c41iKGOnbHzzJJhmdm:pcnHmeIVlKGmwIGD0Z4ghMy9vIH3veZNmKGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJJR2dW:{II\vcJVu\SCjdDCxNk42KG2pL3vnMEBxdyCkaXSu	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTdzNkK5Okc,OTl5MU[yPVY9N2F-
S12	M2jvSmZ2dmO2aX;uJIF{e2G7		MWm0PEBpenN?	NFjB[GVKdmirYnn0bY9vKG:oIHj1cYFvKFOKSDDwZZRpf2G7IHnuJI1wfXOnIGOxNkBk\WyuczDhd5Nme3OnZDDhd{BIVElvbXXkbYF1\WRidILhcpNkemmydHnvcoFtKGGldHn2bZR6KGGodHXyJFQ5KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XliaX6gdJJme2WwY3Wgc4YhOSCvZz;tUEBpfW2jbjDhcJBp[S1zLXHjbYQh\2y7Y3;wdo91\WmwLh?=	NUXLZ4xnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0N\|g2OjdpPkKxOFM5PTJ5PD;hQi=>
Shh Light2	MVfGeY5kfGmxbjDhd5NigQ>?	M3fpflAvOSC3TR?=	Mo\QN\|YhcHK\|	MlTvTY5pcWKrdHnvckBw\iCVbX:tcYVlcWG2ZXSgTIghe2mpbnHscIlv\yCyYYToe4F6KGmwIH3veZNmKFOqaDDMbYdpfDJiY3XscJMh[XO\|ZYPz[YQh[XNic4XwdJJme3Orb36gc4YhT2yrMT3tVm5CKGW6cILld5Nqd25iYYSgNE4yKHWPIH3lZZN2emWmIHHmeIVzKDN4IHjyd{BjgSCUVD3xVGNTKGGwYXz5d4l{Ng>?	NEfsWYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{ezOlA3Oyd-Mke3N\|YxPjN:L3G+
SW1353	MoLJRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	MWCxNEB2VQ>?	NYfYT2N7PDhiaILz	NVPIUoMzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTW\|E{PTNiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYYSgNVAhfU1iYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigS5?	M1nPd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEmxOFU6Lz5{NES5NVQ2QTxxYU6=
DaOY	M1nBfmFvfGmycn;sbYZmemG2aY\lJIF{e2G7	MVKxNEB2VQ>?	NVfGS3RSPDhiaILz	MkjBRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCGYV;ZJINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIF1KDFyIIXNJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmu	NEP3c4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES5NVQ2QSd-MkS0PVE1PTl:L3G+
A549	M1rYcmFvfGmycn;sbYZmemG2aY\lJIF{e2G7	M{TGeFExKHWP	NWnBNGhMPDhiaILz	MoXVRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5JINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIF1KDFyIIXNJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmu	MoLEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OUG0OVkoRjJ2NEmxOFU6RC:jPh?=
HCT116	MW\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?	MX2xNEB2VQ>?	NWPLfXpNPDhiaILz	M2riNmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGG2IEGwJJVOKGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZkv	MmrqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OUG0OVkoRjJ2NEmxOFU6RC:jPh?=
NIH/3T3	NYi3NHRKTnWwY4Tpc44h[XO\|YYm=	M4TNSFExKHWP		MV\Jcohq[mm2aX;uJI9nKEinZHflbI9oKHOrZ37hcIlv\yCrbjDtc5V{\SCQSVivN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KGSxd36gdoVofWyjdHnvckBw\iCvUGTDTFEhdVKQQTDlfJBz\XO\|aX;uJIF1KDFyIIXNMi=>	NYXtNos6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PVE1PTlpPkK0OFkyPDV7PD;hQi=>
MSC	NWDlfFdyTnWwY4Tpc44h[XO\|YYm=	M4XLR\|IxKHSxIEiwJJVO		NVn6RmZTUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegbY4hdW:3c3WgUXNEKGOnbHzzJIF{e2W\|c3XkJIF{KGSxd36gdoVofWyjdHnvckBw\iCjbHvhcIlv\SCyaH;zdIhifGG\|ZTDheEAzOCC2bzC4NEB2VS5?	M1q0S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEmxOFU6Lz5{NES5NVQ2QTxxYU6=
SK-N-MC	NVK0Vm5ueUiWUzDhd5NigQ>?			NXTvZZFLeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJMv	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
TC32	NXrlWYJieUiWUzDhd5NigQ>?			NUTaeHR5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXEN\|MjDj[Yxtey5?	NH20c2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NIH3T3-Luc	M4nC[WZ2dmO2aX;uJIF{e2G7	NWW3U4dvOSC3TR?=	NFL0XpA1QCCqcoO=	NYWxR4hOUW6qaXLpeIlwdiCxZjDzcY8udWWmaXH0[YQhcGWmZ3Xoc4che2mpbnHsbY5oKHCjdHj3ZZkhcW5ibX;1d4UhVkmKM2SzMWx2[yClZXzsd{Bie3Onc4Pl[EBieyCmb4fudoVofWyjdHnvckBw\iCJbHmgcXJPSSCneIDy[ZN{cW:wIHH0JFEhfU1iYX\0[ZIhPDhiaILzJIJ6KHKnYXyteIlu\SCSQ2KgZY5idHm\|aYOu	NWXZVVR4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0PVk1QDNpPkK5OFk6PDh\|PD;hQi=>
C3H10T1/2	NVnLfXJUTnWwY4Tpc44h[XO\|YYm=		M1vuTFI1KGi{cx?=	NU\DPJZoUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeT3t[YRq[XSnZDDHUGkyKG2UTlGg[ZhxemW\|c3nvckBqdiCvb4Xz[UBEO0hzMGSxM\|Ih[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IGLUMXBEWiCjbnHsfZNqeyCrbjDwdoV{\W6lZTDv[kApOVJuM3HSMFRUNDejUjmtO4EudWW2aInsMVEuMCiUKT22MY1mfGi7bHjldJRidi1{LYnsLY9kfGGqeXTyc{0yUC2rbnTlck01NXmuIEOtbJllem:6eXLlcppw[XSnLh?=	M2P6RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{OwPVg1Lz5{NEezNFk5PDxxYU6=
C3H10T1/2	M2TUXWZ2dmO2aX;uJIF{e2G7		NETwZlczPCCqcoO=	NVjWWJZDUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeT3t[YRq[XSnZDDHUGkyKG2UTlGg[ZhxemW\|c3nvckBqdiCvb4Xz[UBEO0hzMGSxM\|Ih[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IGLUMXBEWiCjbnHsfZNqeyCrbjDwdoV{\W6lZTDv[kBXTDNw	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd\|MEm4OEc,OjR5M{C5PFQ9N2F-
NIH/3T3	MWfGeY5kfGmxbjDhd5NigQ>?	NV:weotwOTByIH7N	M3LSXVM3KGi{cx?=	MV\Jcohq[mm2aX;uJI9nKGinZHflbI9oKHOrZ37hcIlv\yCyYYToe4F6KGmwIH3veZNmKE6LSD:zWFMh[2WubIOgZZN{\XO\|ZXSgZZMh\G:5boLl[5Vt[XSrb36gc4YhW2iqLXnu[JVk\WRiR3zpNUBuWk6DIHX4dJJme3Orb36gcIV3\Wy\|IHH0JFExOCCwTTDh[pRmeiB\|NjDodpMh[nliUmStdXBEWiCjbnHsfZNqey5?	NHXS[\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi3N\|MxOyd-Mki4O\|M{ODN:L3G+
C3H10T1/2	MUHGeY5kfGmxbjDhd5NigQ>?	MUKxNFAhdk1?	M1PSXVM3KGi{cx?=	M{nKcWlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViQ{PINVBVOS9{IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTve45z\We3bHH0bY9vKG:oIGPobE1qdmS3Y3XkJGdtcTFibWLORUBmgHC{ZYPzbY9vKGyndnXsd{BifCBzMECgcm0h[W[2ZYKgN\|YhcHK\|IHL5JHJVNXGSQ2KgZY5idHm\|aYOu	M12wUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEezN\|A{Lz5{OEi3N\|MxOzxxYU6=
NIH/3T3	NF;LRlhHfW6ldHnvckBie3OjeR?=	MVSxNFAhdk1?	M3fQTVM3KGi{cx?=	NIjtU4lKdmirYnn0bY9vKG:oIHjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIF7JTE8{XDNiY3XscJMh[XO\|ZYPz[YQh[XNiZH;3cpJm\3WuYYTpc44hd2ZiU3joMYlv\HWlZXSgdJRkcDFibWLORUBmgHC{ZYPzbY9vKGyndnXsd{BifCBzMECgcm0h[W[2ZYKgN\|YhcHK\|IHL5JHJVNXGSQ2KgZY5idHm\|aYOu	M1KyOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEezN\|A{Lz5{OEi3N\|MxOzxxYU6=
C3H10T1/2	NHr2XZNHfW6ldHnvckBie3OjeR?=	NX7U[lZiOTByIH7N	NWX3b\|llOzZiaILz	NX\TNWpkUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W\|ZTDDN2gyOFRzL{KgZ4VtdHNiYYPz[ZN{\WRiYYOg[I94dnKnZ4XsZZRqd25ib3[gV4hpNWmwZIXj[YQheHSlaEGgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCjdDCxNFAhdk1iYX\0[ZIhOzZiaILzJIJ6KFKWLYHQR3Ih[W6jbInzbZMv	M2CxWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEezN\|A{Lz5{OEi3N\|MxOzxxYU6=
medulloblastoma cell	MoPiRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	MW\1dEB1dyB\|MDD1US=>	NEHmb3Y4OiCqcoO=	MkXvRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCSdHPoL{8uKHB3Mz2vMUBu\WS3bHzvZoxie3SxbXGgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygdJJwdGmoZYLheIlwdiC3cDD0c{A{OCC3TTDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7Lh?=	NYjUXoVoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4O\|M{ODNpPkK4PFc{OzB\|PD;hQi=>
medulloblastoma cell	MX;BdI9xfG:\|aYOgZZN{[Xl?			Mny1TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDtc5V{\SCSdHPoL{8uKHB3Mz2vMUBu\WS3bHzvZoxie3SxbXGgZ4VtdHNiaX3wcIFvfGWmIHnuJIF1cHmvaXOgcpVl\SCvb4Xz[UBifCBzMj61JI1oN2upLDDpdEBjcWRiZn;yJFE2KGOxboPlZ5V1cX[nIHThfZMh[nliVGXOSWwh[XO\|YYmu	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh5M{OwN{c,Ojh6N{OzNFM9N2F-
NIH/3T3	NITLT\|dHfW6ldHnvckBie3OjeR?=			NFzxc41KdmirYnn0bY9vKG:oIHjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHX4dJJme3OnZDDpckBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhcGWmZ3Xoc4cucW6mdXPl[EBIdGlvMjDhZ4N2dXWuYYTpc44h[XRidHnwJI9nKHC{aX3hdpkh[2muaXGgZpkhTEGSSTDzeIFqdmmwZzDiZZNm\CClb37mc4NidCCvaXPyc5Nkd3CrYzDhcoFtgXOrcz6=	NWLXNVhERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4NVA2QTFpPkK3PFExPTlzPD;hQi=>
NIH/3T3	NITvW4NHfW6ldHnvckBie3OjeR?=			MmjLTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCQSVivN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gbIVl\2Wqb3etbY5lfWOnZDDTcY8uTUeIUDDjbYxq[XK7IITyZY5{dG:lYYTpc44h[nliRFHQTUB{fGGrbnnu[{Bj[XOnZDDjc45nd2OjbDDtbYNzd3Olb4DpZ{BidmGueYPpd{4>	NYDrZmdHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4NVA2QTFpPkK3PFExPTlzPD;hQi=>
medulloblastoma cell	NYnBeWZXSW62aT30eY1weiCjc4PhfS=>			MXrBcpRqNXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViUITjbEswNSCyNUOtM{0hdWWmdXzsc4Jt[XO2b33hJINmdGy\|IHntdIxidnSnZDDpckBifGi7bXnjJI52\GVibX;1d4Uh[XO\|ZYPz[YQh[XNidIXtc5Ih\3Kxd4ToJIlvcGmkaYTpc44h[XRiMkCgcYcwc2duIIDvJIFldWmwaYP0[ZJm\CC2d3nj[UBl[WmueTD2bYEh\2G4YXflJI1m[XO3cnXkJIV3\XK7IH;0bIVzKGSjeTDkeZJqdmdiY3;tdI92dmRiZH;zbY5oNg>?	NEnsWWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUezPVcyPCd-Mkm3N\|k4OTR:L3G+
C3H10T1/2	MXPGeY5kfGmxbjDhd5NigQ>?	M2XUflQvOSC2bzCxNFAxKG6P		NFLGZnNCdGyxc4TldolkKGmwaHnibZRqd25ib3[gV41wKGmwIH3veZNmKEN\|SEGwWFEwOiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJB2em2xcoDoZY1qdmVvaX7keYNm\CCJbHmxJJRz[W6\|Y4LpdJRqd26jbDDhZ5Rqfmm2eTDheEA1NjFidH:gNVAxOCCwTTDifUByWEO{IHHuZYx6e2m\|Lh?=	NF:0dpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C3OFU1OSd-MkOwO\|Q2PDF:L3G+
C3H10T1/2	MXfGeY5kfGmxbjDhd5NigQ>?	MWm0MlEhfG9iMUCwNEBvVQ>?		MluxR49ueGW2aYTpeoUhcW6qaXLpeIlwdiCxZjDTcY8hcW5ibX;1d4UhSzOKMUDUNU8zKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gV2FINWmwZIXj[YQhT2yrMTD0doFve2O{aYD0bY9v[WxiYXP0bZZqfHliYYSgOE4yKHSxIEGwNFAhdk1iYomgdXBEWiCjbnHsfZNqey5?	MnLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyN{S1OFEoRjJ\|MEe0OVQyRC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Fas / DR4 / DR5 / Cleaved PARP / Bcl-2 / Cleaved caspase-3 / PDGFRα; PubMed: 22087285 PLoS One Pancreatic CSCs were treated with GDC-0449 (0, 1, 5 and 10 µM) for 48 h. The expression of Fas, DR4/TRAIL-R1, DR5/TRAIL-R2, PARP cleavage, Bcl-2, and Caspase-3 by the Western blot analysis. β-Actin was used as a loading control. p-GSK3β / GSK3β / p-Akt / Akt / Gli1; PubMed: 27143997 Oxid Med Cell Longev Cells were pretreated with or without 30 μM GDC-0449 for 2 h before TMT treatment. After incubation with 3.75 μM TMT for another 24 h, the expression levels of proteins were determined through Western blot analysis. Gli1 / SOX2 / OCT4; PubMed: 26418365 Stem Cells The activation of Hedgehog pathways and CSC markers were tested by immunoblotting analysis in Hs578T and BT549 cells. β‐Actin was used as a loading control. p53 / Cyclin D1 / p21; PubMed: 28195165 Sci Rep GDC-0449 treatment affected the expression levels of cell cycle-related protein levels. U251 cells were treated with 0.1% DMSO or GDC-0449 at the indicated concentrations for 24 h. Cells were then harvested and examined using Western blot analysis with the indicated antibodies. Bcl-2 / Bax; PubMed: 28195165 Sci Rep GDC-0449 treatment affected the expression levels of cell cycle-related protein levels. U251 cells were treated with 0.1% DMSO or GDC-0449 at the indicated concentrations for 24 h. Cells were then harvested and examined using Western blot analysis with the indicated antibodies.	22087285 27143997 26418365 28195165
Immunofluorescence	Gli1 / Gli2; PubMed: 22087285 PLoS One GDC-0449 inhibits expression of Gli1 and Gli2 in human pancreatic CSCs. The cells were seeded on fibronectin-coated coverslips and treated with GDC-0449 (10 µM) for 48 h. Subsequently, cells were fixed with 4% paraformaldehyde, blocked in 10% normal goat serum and stained with Gli1 and Gli2 primary antibodies (1∶100) for 16 h at 4°C and washed with PBS. Afterwards, cells were incubated with fluorescently labeled secondary antibody (1∶200) along with DAPI (1 mg/ml) for 1 h at room temperature and cells were mounted and visualized under a fluorescent microscope. For better visuality, the color of DAPI was changed from blue to red.	22087285
Growth inhibition assay	Cell viability; PubMed: 29042665 Sci Rep GDC-0449 improves the anti-proliferation activity in NIH-3T3 cells but not in BxPC-3, Panc-1, MIAPaca-2 and SW1990 cells when cultured alone. The cytotoxicities of GDC-0449, Dox or Dox with GDC-0449 (5 μM or 10 μM) were measured by performing a 48-h MTT assay in BxPC-3 (A), Panc-1 (B), MIAPaca-2 (C), SW1990 (D) and NIH-3T3 (E) cells. Apoptosis rate was detected by flow cytometry (Annexin V staining) analysis after treatment with Dox (200 nM) with or without GDC-0449 for 24 h (F). Data are presented as the mean ± SD. P < 0.05, *P < 0.01.	29042665

体内研究

GDC-0449已经用于治疗动物模型的成髓细胞瘤。^[2] GDC-0449 抑制原代胰腺移植瘤生长，但是不抑制细胞增殖。GDC-0449按25 mg/kg 以上剂量口服给药髓母细胞瘤Ptch(+/-)异体移植物模型，引起细胞衰退，按92 mg/kg剂量处理两种配位体依赖的结肠直肠癌模型D5123和1040830，每天处理两次，抑制肿瘤生长。分析Hh通路活性和 PK/PD 模型显示GDC-0449抑制 Gli1，IC50值与GDC-0449作用于髓母细胞瘤和D5123模型的IC50值差不多(分别为0.165 μM ±11.5% 和0.267 μM ±4.83%)。^[4]

细胞实验：^[2]	- 合并 Cell lines: MDCKII细胞 Concentrations: 20 μM Incubation Time: 2小时 Method: MDCKII细胞按每孔3x10⁵密度接种在24孔板中。培养液包含不同药物，实验组为50 µM VP,50 µM吲哚美辛,或者20 µM GDC-0449溶解在DMSO中，对照组只含有DMSO。然后加入非荧光的钙黄绿素-AM，最终浓度达到1.0 µM。然后在37^oC温育2小时。细胞用含Ca²⁺,Mg²⁺的Hank's平衡盐溶液buffer冲洗2次，然后震荡1小时溶解在含0.01% Triton X-100的磷酸缓冲液中，然后放在4^oC下过夜。溶解的物质然后转移到96孔板上，钙黄绿素引起的荧光信号用分光光度法定量。所有的实验操作需在暗中进行，所有的读数用平均值±SEM表示。 (Only for Reference)
动物实验：^[4]	- 合并 Animal Models: Ptch(+/-)异体移植物模型 Dosages: 25 mg/kg,92 mg/kg Administration: 口服 (Only for Reference)

参考文献

[4] Wong H, et al. Clin Cancer Res. 2011, 17(14), 4682-4692.

- 合并

溶解度 (25°C)

体外	DMSO	84 mg/mL (199.38 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O	12.5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Vismodegib (GDC-0449) SDF

分子量	421.3
化学式	C₁₉H₁₄Cl₂N₂O₃S
CAS号	879085-55-9
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03610022	Recruiting	Drug: Treatment with vismodegib	Metastatic Basal Cell Carcinoma\|Locally Advanced Basal Cell Carcinoma	University Hospital Bordeaux	September 3 2018	Phase 4
NCT03035188	Active not recruiting	Drug: Vismodegib	Basal Cell Carcinoma	SRH Wald-Klinikum Gera GmbH	January 2017	Phase 2
NCT02781389	Active not recruiting	--	Basal Cell Carcinoma	University Hospital Essen\|OnkoDataMed GmbH	April 29 2016	--
NCT02593760	Completed	Other: Placebo\|Drug: Ruxolitinib\|Drug: Vismodegib	Myelofibrosis	Hoffmann-La Roche	January 25 2016	Phase 1
NCT02648048	Completed	Drug: Pirfenidone\|Drug: Vismodegib	Idiopathic Pulmonary Fibrosis	Hoffmann-La Roche	January 15 2016	Phase 1
NCT02366312	Completed	Drug: vismodegib	Keratocystic Odontogenic Tumor	NYU College of Dentistry\|Genentech Inc.	October 27 2015	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

选择性强的Smoothened抑制剂

PF-5274857 : Smoothened-selective, IC50=5.8 nM.
用于临床的Smoothened抑制剂

LDE225 (NVP-LDE225,Erismodegib) : Phase III for Hh-pathway activated relapsed Medulloblastoma (MB).
最新的Smoothened抑制剂

GANT61 : Inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation.
Smoothened激活剂

Purmorphamine : Directly binds and activates Smoothened, and blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM.

研究领域

产品类型

定制您的化合物库

Vismodegib (GDC-0449)

客户使用Selleck生产的Vismodegib (GDC-0449)发表文献140篇：

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Vismodegib (GDC-0449) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-01-06)

技术支持

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

相关Hedgehog/Smoothened产品